Entera Bio Ltd. (NASDAQ:ENTX – Get Rating) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 228,200 shares, a growth of 22.8% from the March 15th total of 185,900 shares. Based on an average daily volume of 228,500 shares, the short-interest ratio is currently 1.0 days. Currently, 1.0% of the company's shares are sold short.

Insider Buying and Selling at Entera Bio

In other news, CEO Miranda Jayne Toledano purchased 30,000 shares of Entera Bio stock in a transaction dated Tuesday, April 4th. The shares were bought at an average cost of $1.01 per share, with a total value of $30,300.00. Following the completion of the transaction, the chief executive officer now directly owns 86,800 shares in the company, valued at approximately $87,668. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 5.15% of the company's stock.

Institutional Trading of Entera Bio

Several hedge funds and other institutional investors have recently modified their holdings of ENTX. Renaissance Technologies LLC grew its holdings in shares of Entera Bio by 555.4% during the fourth quarter. Renaissance Technologies LLC now owns 139,600 shares of the company's stock worth $102,000 after buying an additional 118,300 shares in the last quarter. Millennium Management LLC boosted its position in Entera Bio by 358.5% during the 4th quarter. Millennium Management LLC now owns 46,000 shares of the company's stock worth $34,000 after acquiring an additional 35,968 shares during the last quarter. Finally, PNC Financial Services Group Inc. bought a new position in shares of Entera Bio during the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 20.12% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Entera Bio in a report on Tuesday, April 4th.

Entera Bio Stock Down 2.3 %

ENTX traded down $0.02 during trading on Thursday, hitting $0.85. The company had a trading volume of 27,324 shares, compared to its average volume of 212,372. The company has a market capitalization of $24.48 million, a PE ratio of -1.89 and a beta of 1.83. Entera Bio has a one year low of $0.47 and a one year high of $2.95. The firm's 50-day moving average price is $1.00 and its 200 day moving average price is $0.86.

About Entera Bio

(Get Rating)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Read More

• Get a free copy of the StockNews.com research report on Entera Bio (ENTX)
• Finding New Technology to Invest in: A Guide
• Genuine Parts Company Is Genuinely A Good Buy
• Healthcare Sector: Overview and Keys to Investing
• Can D.R. Horton Shares Raise The Roof, Or Is This The Ceiling?
• American Express Growth Riding On Joyful Consumer Spending

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.